Search

Simple Summary In order to treat COVID-19 disease, various drugs have been used as repurposed drugs, because no drug directly targets against the SARS-CoV-2 virus. The aim of this study was to evaluate the relationship between the drugs used for COVID-19 treatment and liver disturbances, in order to identify any change in liver enzymes during therapy. Patients admitted in an internal medicine department were treated with a complex therapeutic scheme, including antivirals. Beside the follow up for the evolution of the disease, we also monitored the potential occurrence of side effects, especially liver damage. Our results showed that none of the three antivirals that we used produced severe or significant liver disturbances. Our conclusion may be useful in guiding clinical practice, adding more information for the medical community. Abstract (1) Background: The antiviral treatment for COVID-19 disease started to be largely used in 2020 and has been found to be efficient, although it is not specific for SARS-CoV-2 virus. There were some concerns that it may produce liver damage or other side effects. (2) Methods: The aim of this study was to observe if antiviral therapy is affecting liver parameters or producing other side-effects in patients hospitalized for COVID-19 disease. The study included a group of patients hospitalized in the internal medicine department of Oradea Municipal Clinical Hospital, Romania, between August 2020–June 2021, diagnosed with SARS-CoV-2 viral infection by RT-PCR method or rapid antigen test. During hospitalization, patients were treated with a Lopinavir/Ritonavir (Kaletra) combination, or with Favipiravir or Remdesivir. In addition to monitoring the evolution of the disease (clinical and biochemical), also hepatic parameters were analyzed at admission, during hospitalization, and at discharge. (3) Results: In the group of studied patients, the mean value of aspartat aminotrensferase did not increase above normal at discharge, alanin aminotransferase increased, but below twice the normal values, and cholestasis registered a statistically insignificant slight increase. (4) Conclusions: In our study, we found that all three antivirals were generally well tolerated and their use did not alter liver function in a significant manner.

(1) Background: In patients hospitalized with COVID-19 pneumonia, especially moderate and severe forms, a cytokine storm may occur, characterized by the worsening of symptoms and the alteration of biological parameters on days 8–12 of the disease. The therapeutic options for cytokine storms are still controversial, requiring further clarification; (2) Methods: Our study included 344 patients with moderate and severe pneumonia admitted to the internal medicine department who developed a cytokine storm (diagnosed by clinical and biochemical criteria). In group A, 149 patients were treated with Remdesivir and Tocilizumab (together with other drugs, including corticosteroids, antibiotics and anticoagulants), and in group B, 195 patients received Remdesivir and Anakinra. Patients were monitored clinically and by laboratory tests, with the main biochemical parameters being CRP (C-reactive protein), LDH (lactic dehydrogenase) and ferritin; (3) Results: Patients were followed up from a clinical point of view and also by the measurement of CRP, LDH and ferritin at the beginning of therapy, on days three to four and on the tenth day. In both groups, we registered a clinical improvement and a decrease in the parameters of the cytokine storm. In group A, with the IL-6 antagonist Tocilizumab, the beneficial effect occurred faster; in group B, with the IL-1 antagonist Anakinra, the beneficial effect was slower. (4) Conclusions: The use of the immunomodulators, Tocilizumab and Anakinra, in the cytokine storm showed favorable effects, both clinical and biochemical.

Interaction mechanisms and biological effects that different types of radiation could exert upon humans have been studied by many authors. Different studies investigated the reactions of various types of electrical equipment, power lines, mobile phones and other upon humans, their influence on the brain functions, public health or if magnetic fields (MFs) can be used for pain relief. Some authors found out that electromagnetic fields (EMFs) might be a factor which determined a number of chronic illnesses (cancer, heart diseases and sleep disorders) even to low intensity. But on the other side, because the EMFs are part of nature, being radiated by human body and its organs, the quality and intensity of the energy can either support or destroy health. Magnetic fields and electromagnetic fields are useful modalities to treat various pathologies and diseases. A number of clinical studies, in vivo animal experiments and in vitro cellular and membrane researches, suggested that EMFs and MFs stimulation reduce pain and accelerate the healing process. However, EMFs are still not widely used in clinical medicine. It is accepted that pain control occurs via a series of integrated stages, each with particular objectives essential to the tissue/system repairing processes. Electric and magnetic stimulation have been proven to provide beneficial and reproducible healing effects even when other methods have failed. As for the MFs, this is an excellent possibility as a non – invasive method to control and treat pain. Magnetic stimulation of a patient is different from drug treatment. As technology proliferates and people use more and more electronic devices, some researchers suspect EMFs contribute to a subtle assault upon people’s immune system and health. This paper aims to review the way that electromagnetic fields and other types of radiations interaction at molecular level with human organism.